Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Kurt von Emster Biography and Net Worth

Director of CymaBay Therapeutics

Kurt von Emster, CFA has been a member of our Board of Directors since April 2009 and brings over 25 years of experience in life science investment. Mr. von Emster is a Managing Partner at Abingworth LLP, a venture capital firm, since January 2015 and as Managing Partner since July 2015. Prior to joining Abingworth, Mr. von Emster was a co-founder and Partner of venBio LLC, a venture capital firm, from May 2009 until January 2015. In 2001, Mr. von Emster became a General Partner at MPM Capital, a biotechnology private equity firm, and launched the MPM BioEquities Fund, a crossover public and private biotechnology hedge fund. He was the portfolio manager of this fund from inception in 2001 until his departure in 2009. Mr. von Emster’s investment career started in 1989 at Franklin Templeton Investments where he founded and managed several health and biotechnology funds in the 1990s. Mr. von Emster currently serves on the board of directors of Tizona Therapeutics, Inc., Orbus Therapeutics, Inc., Jasper Therapeutics, Inc., SFJ Pharmaceuticals Inc. and Launch Therapeutics, Inc., and previously served on the board of directors of Trishula Therapeutics, Inc., Vera Therapeutics, Inc., Vaxcyte, Inc., and CRISPR Therapeutics AG. Mr. von Emster holds a Bachelor of Science in Business and Economics and is a Chartered Financial Analyst.

What is Kurt von Emster's net worth?: The estimated net worth of Kurt von Emster is at least $2.92 million as of September 29th, 2023. Mr. von Emster owns 90,000 shares of CymaBay Therapeutics stock worth more than $2,923,200 as of April 27th. This net worth approximation does not reflect any other investments that Mr. von Emster may own. Learn More about Kurt von Emster's net worth.
How do I contact Kurt von Emster?: The corporate mailing address for Mr. von Emster and other CymaBay Therapeutics executives is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. CymaBay Therapeutics can also be reached via phone at (510) 293-8800 and via email at [email protected]. Learn More on Kurt von Emster's contact information.
Has Kurt von Emster been buying or selling shares of CymaBay Therapeutics?: Kurt von Emster has not been actively trading shares of CymaBay Therapeutics within the last three months. Most recently, Kurt Von Emster sold 15,921 shares of the business's stock in a transaction on Friday, September 29th. The shares were sold at an average price of $15.68, for a transaction totalling $249,641.28. Following the completion of the sale, the director now directly owns 90,000 shares of the company's stock, valued at $1,411,200. Learn More on Kurt von Emster's trading history.
Who are CymaBay Therapeutics' active insiders?: CymaBay Therapeutics' insider roster includes Janet Dorling (Director), Dennis Kim (Insider), Charles McWherter (Insider), Daniel Menold (VP), Paul Quinlan (General Counsel), Sujal Shah (CEO), and Kurt von Emster (Director). Learn More on CymaBay Therapeutics' active insiders.
Are insiders buying or selling shares of CymaBay Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 480,648 shares worth more than $7,806,823.97. The most recent insider tranaction occured on February, 12th when Director Janet Dorling sold 6,000 shares worth more than $191,820.00. Insiders at CymaBay Therapeutics own 7.0% of the company. Learn More about insider trades at CymaBay Therapeutics.
Information on this page was last updated on 2/12/2024.

Kurt von Emster Insider Trading History at CymaBay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/29/2023	Sell	15,921	$15.68	$249,641.28	90,000
12/18/2018	Sell	142,381	$7.89	$1,123,386.09	90,000
6/5/2018	Sell	920	$12.51	$11,509.20	90,000
3/5/2018	Sell	13,353	$15.51	$207,105.03	90,000
2/14/2018	Sell	218,057	$15.89	$3,464,925.73
2/7/2018	Sell	40,763	$12.35	$503,423.05	90,000
2/5/2018	Sell	18,831	$12.14	$228,608.34
2/2/2018	Sell	90,098	$12.15	$1,094,690.70
1/31/2018	Sell	97,639	$12.22	$1,193,148.58	90,000
1/25/2018	Sell	39,438	$12.18	$480,354.84	90,000
1/22/2018	Sell	138,253	$10.40	$1,437,831.20	90,000
1/19/2018	Sell	144,216	$10.25	$1,478,214.00	90,000
1/5/2018	Sell	4,300	$10.21	$43,903.00	90,000
12/22/2017	Sell	173,192	$9.41	$1,629,736.72	90,000
11/10/2017	Sell	50,048	$9.26	$463,444.48	90,000
10/31/2017	Sell	59,209	$9.27	$548,867.43	90,000
10/3/2017	Sell	108,876	$7.85	$854,676.60
9/29/2017	Sell	211,124	$8.09	$1,707,993.16

Kurt von Emster Buying and Selling Activity at CymaBay Therapeutics

CymaBay Therapeutics Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Today's Range

Now: $32.48

$32.48

50 Day Range

MA: $32.40

$32.17

$32.48

2 Week Range

Now: $32.48

$7.26

$32.50

Volume

73 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad